Oligomerix Announces Late-Breaking Presentation at 2021 Clinical Trials on Alzheimer's Disease (CTAD) Conference
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company will deliver a virtual oral presentation at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in Boston on November 9-12, 2021.
The late-breaking presentation titled “Oral treatment with OLX-07010, a small molecule inhibitor of tau self-association, reduced tau aggregation to baseline in a therapeutic study of aged tau P301L JNPL3 mice” will be available on November 9 at 8:00am EST.
About Oligomerix’s Lead Program
Oligomerix’s lead candidate is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process thought to be important in the development of Alzheimer’s disease and other neurodegenerative disorders. The lead candidate has demonstrated efficacy in animal models of tau-mediated neurodegeneration. Preclinical safety studies are completing and Phase 1a clinical studies are planned to initiate in the second quarter of 2022.
About Oligomerix, Inc.
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease.
Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association, in order to develop medicines that are easy to administer and cost effective. The Oligomerix portfolio of compounds are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA.
Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on Twitter and LinkedIn.
Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit our new website at https://oligomerix.com/.
Chief Commercial Officer
James Moe, Ph.D., MBA
President and CEO
212-568-0365 Ext. 104